ALIADA THERAPEUTICS

Serial Number 90832349
606

Registration Progress

Application Filed
Jul 16, 2021
Under Examination
Aug 16, 2022
Approved for Publication
Jun 21, 2022
Published for Opposition
Jun 21, 2022
Registered

Re-Apply for This Trademark

This trademark is no longer active. You may be able to file a new application for the same or similar mark.
Mark: ALIADA THERAPEUTICS
Previous Owner: Aliada Therapeutics, Inc.
Classes: 005, 042

Trademark Image

ALIADA THERAPEUTICS

Basic Information

Serial Number
90832349
Filing Date
July 16, 2021
Published for Opposition
June 21, 2022
Abandonment Date
September 22, 2025
Drawing Code
4

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Sep 22, 2025
Classes
005 042

Rights Holder

Aliada Therapeutics, Inc.

03
Address
501 Boylston Street
9th Floor
Boston, MA 02116

Ownership History

Aliada Therapeutics, Inc.

Original Applicant
03
Boston, MA

Aliada Therapeutics, Inc.

Owner at Publication
03
Boston, MA

Legal Representation

Attorney
Cheryl A. Withycombe

USPTO Deadlines

No Upcoming Deadlines

No upcoming deadlines found for this trademark.

Application History

40 events
Date Code Type Description Documents
Sep 22, 2025 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Loading...
Sep 22, 2025 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Sep 15, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
May 27, 2025 EX5G S SOU EXTENSION 5 GRANTED Loading...
Feb 10, 2025 EXT5 S SOU EXTENSION 5 FILED Loading...
May 27, 2025 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Feb 11, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Feb 4, 2025 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Feb 4, 2025 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Feb 4, 2025 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Jul 15, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jul 15, 2024 EX4G S SOU EXTENSION 4 GRANTED Loading...
Jul 15, 2024 EXT4 S SOU EXTENSION 4 FILED Loading...
Jul 15, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jan 19, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jan 17, 2024 EX3G S SOU EXTENSION 3 GRANTED Loading...
Jan 17, 2024 EXT3 S SOU EXTENSION 3 FILED Loading...
Jan 17, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jul 18, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jul 15, 2023 EX2G S SOU EXTENSION 2 GRANTED Loading...
Jul 15, 2023 EXT2 S SOU EXTENSION 2 FILED Loading...
Jul 15, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jan 7, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jan 5, 2023 EX1G S SOU EXTENSION 1 GRANTED Loading...
Jan 5, 2023 EXT1 S SOU EXTENSION 1 FILED Loading...
Jan 5, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Aug 16, 2022 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Jun 21, 2022 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jun 21, 2022 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jun 1, 2022 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
May 13, 2022 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
May 11, 2022 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
May 11, 2022 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
May 11, 2022 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Apr 14, 2022 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Apr 14, 2022 GNRT F NON-FINAL ACTION E-MAILED Loading...
Apr 14, 2022 CNRT R NON-FINAL ACTION WRITTEN Loading...
Apr 7, 2022 DOCK D ASSIGNED TO EXAMINER Loading...
Sep 20, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jul 20, 2021 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
pharmaceuticals and therapeutic pharmaceuticals for the treatment of neurological conditions; pharmaceuticals and therapeutic pharmaceuticals for the treatment and prevention of immunological conditions; pharmaceuticals and therapeutic pharmaceuticals for the treatment of cancer; pharmaceuticals and therapeutic pharmaceuticals for the treatment and prevention of ophthalmic conditions
Class 042
research and development of pharmaceuticals and therapeutics in the fields of neurology, immunology, oncology and ophthalmology

Additional Information

Translation
The English translation of ALIADA in the mark is ALLIED.

Classification

International Classes
005 042

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"THERAPEUTICS"